Settlement Cuts Insulin Costs by $7 Billion Over 10 Years

Millions of Americans who depend on insulin and other prescription drugs just got a major financial lifeline.

The Federal Trade Commission secured a groundbreaking settlement with Express Scripts, one of the nation's largest pharmacy benefit managers. The agreement requires fundamental changes to business practices that artificially inflated drug prices, particularly for insulin.

For years, the system worked against patients. Express Scripts preferred drugs with higher list prices because they generated bigger rebates, which benefited the company but hurt people whose copays and coinsurance were tied to those inflated prices.

Now that changes. Under the settlement, Express Scripts must stop favoring expensive versions of drugs over identical lower-cost options.

The company will also offer plans where patients pay based on the actual net cost of drugs rather than inflated list prices. This single change addresses a problem that has forced many Americans to ration life-saving medications.

Community pharmacies get relief too. Express Scripts must transition to a fairer payment model based on actual drug costs plus dispensing fees. This new revenue stream will help local pharmacies that have been squeezed by the current system.

The settlement includes major transparency requirements. Express Scripts must provide detailed drug-level reporting to plan sponsors and disclose payments made to brokers. Plan sponsors will also get options to move away from rebate guarantees that drove up costs.

In an unusual move, the agreement requires Express Scripts to bring its group purchasing organization back from Switzerland to the United States. This reshoring will return more than $750 billion in purchasing activity to American soil over the life of the order.

The Ripple Effect

This settlement creates a blueprint for how the entire pharmacy benefit manager industry could operate more fairly. Two other major companies face similar allegations, and this agreement shows that transparency and patient-first pricing are possible.

The changes benefit everyone except the middlemen who profited from complexity. Patients save money at the pharmacy counter. Community pharmacies earn fair compensation. Plan sponsors get the information they need to make better decisions.

For someone managing diabetes or other chronic conditions, lower out-of-pocket costs mean fewer impossible choices between medication and other necessities. It means better health outcomes when people can actually afford to take their prescribed medications.

The settlement proves that regulatory action can create real financial relief for ordinary Americans struggling with healthcare costs.